[Preparation of a gel-forming ointment base applicable to the recovery stage of bedsore and clinical evaluation of a treatment method with different ointment bases suitable to each stage of bedsore].
An ointment base for better treatment of bedsores was developed to improve the release rate of minocycline hydrochloride (MH) and the water absorption capacity using various types of hydrophobic to hydrophilic ointment bases. The effect of purified lanolin (PL) on the release behavior of MH from a hydrophilic ointment (HO) base was the primary focus. It was found that the drug release rate from the ointment base was modified according to the method of preparation of the ointment base and the type of cyclodextrins admixed. The physicochemical properties, such as viscosity, elution volume, and water absorption, of the ointment base were also modified by those factors. To develop an ointment formulation suitable for the recovery stages of bedsores, including the proliferation period of granulation and the formative period of epidermis, the physicochemical properties of Macrogol ointment containing various hydrophilic polymers, which have gel-forming ability, were tested. A novel ointment base suitable for the treatment in the recovery stage of bedsores was developed using hydrophobically modified hydroxypropyl methylcellulose (HM-HPMC). Considerably sustained release of MH (T50 of 170 at a min) was attained with a macrogol ointment mixed with HM-HPMC and Carbopol formulation ratio of 3:7. We clinically evaluated the effectiveness of bedsore treatment by applying different ointment bases to patients with different stages of bedsores.
Department of Pharmacy, Takayama Red Cross Hospital, 3-11 Tenman-cho, Takayama City 506-8550, Japan. eroshige@hidanet.ne.jp
Masato
M
Shigeyama
D000042:Absorption; D000180:Acrylic Resins; D055598:Chemical Phenomena; D002626:Chemistry, Pharmaceutical; D002627:Chemistry, Physical; D018849:Controlled Clinical Trials as Topic; D003505:Cyclodextrins; D003692:Delayed-Action Preparations; D015195:Drug Design; D005782:Gels; D006801:Humans; D065347:Hypromellose Derivatives; D007809:Lanolin; D008747:Methylcellulose / Q000031:analogs & derivatives; D008911:Minocycline / Q000627:therapeutic use; D009823:Ointment Bases; D009824:Ointments; D011092:Polyethylene Glycols; D011145:Polyvinyls; D003668:Pressure Ulcer / Q000145:classification / Q000188:drug therapy*; D012720:Severity of Illness Index; D014867:Water
D000180:Acrylic Resins; D003505:Cyclodextrins; D003692:Delayed-Action Preparations; D005782:Gels; D009823:Ointment Bases; D009824:Ointments; D011145:Polyvinyls; D014867:Water; C006912:carboxypolymethylene; D065347:Hypromellose Derivatives; D011092:Polyethylene Glycols; D007809:Lanolin; D008747:Methylcellulose; D008911:Minocycline